Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Harefuah ; 161(1): 17-20, 2022 Jan.
Artículo en Hebreo | MEDLINE | ID: mdl-35077054

RESUMEN

INTRODUCTION: Adenocarcinomas of the gastroesophageal junction (GEJ) are tumors whose incidence rates increased significantly in recent years. These tumors have a poor prognosis, and are treated with a palliative approach when diagnosed in an advanced stage. Some tumors overexpress PDL-1 proteins which are partially responsible for the "immune escape" of tumor cells. However, this over-expression enables the use of an immunotherapeutic treatment approach. Immunotherapy using anti-PD1/PDL-1 shows promising results in patients with metastatic GEJ tumors. In the present case report, we describe a young patient who was diagnosed with a non-resectable GEJ adenocarcinoma and was found to have almost 100% positivity for PDL-1 in the tumor biopsy, using standard immunohistochemistry. The patient had rapid and complete response to the anti-PD1 antibody treatment with further development of immune mediated side effects.


Asunto(s)
Adenocarcinoma , Neoplasias Esofágicas , Neoplasias Gástricas , Adenocarcinoma/terapia , Neoplasias Esofágicas/terapia , Unión Esofagogástrica , Humanos , Inmunoterapia/efectos adversos , Neoplasias Gástricas/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA